Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.44 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4776742 | 0.98 | CYP3A4 (0.51) | CYP3A4CYP2D6SLC6A3SLC6A2SLC6A1 | |
| SCHEMBL15257813 | 0.88 | CYP3A4 (0.59) | CYP3A4CYP2D6SLC6A3SLC6A2SLC6A1 | |
| SCHEMBL3368134 | 0.88 | CYP3A4 (0.59) | CYP3A4CYP2D6SLC6A3SLC6A2SLC6A1 | |
| SCHEMBL29145964 | 0.85 | CYP3A4 (0.56) | CYP3A4CYP2D6SLC6A3SLC6A2SLC6A1 | |
| SCHEMBL7741578 | 0.85 | CYP3A4 (0.56) | CYP3A4CYP2D6SLC6A3SLC6A2SLC6A1 | |
| SCHEMBL5783785 | 0.84 | TAAR1 (0.53) | CYP3A4CYP2D6SLC6A3SLC6A2SLC6A1 | |
| SCHEMBL7739742 | 0.83 | CYP3A4 (0.55) | CYP3A4CYP2D6SLC6A3SLC6A2SLC6A1 | |
| SCHEMBL7739723 | 0.83 | CYP3A4 (0.55) | CYP3A4CYP2D6SLC6A3SLC6A2SLC6A1 | |
| SCHEMBL7738599 | 0.83 | CYP3A4 (0.55) | CYP3A4CYP2D6SLC6A3SLC6A2SLC6A1 | |
| SCHEMBL7739778 | 0.83 | CYP3A4 (0.55) | CYP3A4CYP2D6SLC6A3SLC6A2SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301299-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2019-05-28 | — | — | US | disclosed |
| US-10301299-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180093977-A1 | Glycosidase Inhibitors | MERCK PATENT GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180093977-A1 | Glycosidase Inhibitors | MERCK PATENT GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| CN-105143222-B | Glycosidase inhibitor | 默克专利有限公司 | 2018-02-02 | — | — | CN | disclosed |
| US-9879001-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-9879001-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| US-9586928-B2 | Modulators of the nuclear hormone receptor ROR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160031871-A1 | Glycosidase Inhibitors | YU HENRY (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031871-A1 | Glycosidase Inhibitors | YU HENRY (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2418950-A1 | COMPOUNDS AND METHODS FOR MODULATING ACTIVITY OF CALCIUM RELEASE CHANNELS | State Of Oregon By&Through The State Board Of Higher Education On Behalf Of Portland State Unv. (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7879840-B2 | Ryanodine receptors (RyRs) modulators comprising 1,4-benzothiazepine derivatives, that regulate calcium channel functioning in cells, used for the treatment of cardiovascular disorders and muscular disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879840-B2 | Ryanodine receptors (RyRs) modulators comprising 1,4-benzothiazepine derivatives, that regulate calcium channel functioning in cells, used for the treatment of cardiovascular disorders and muscular disorders | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-02-01 | — | — | US | disclosed |
| WO-2010120382-A1 | COMPOUNDS AND METHODS FOR MODULATING ACTIVITY OF CALCIUM RELEASE CHANNELS | STATE OF OREGON BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010120382-A1 | COMPOUNDS AND METHODS FOR MODULATING ACTIVITY OF CALCIUM RELEASE CHANNELS | STATE OF OREGON BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF PORTLAND STATE UNIVERSITY (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2007-07-26 | — | — | US | disclosed |
| CN-1390201-A | cyclic amine compounds as CCR5 antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031871-A1 | Glycosidase Inhibitors | GAA, BACE1, GBA3 | CYP3A4 1050/4885CYP2D6 438/4885SLC6A3 1218/4885 |
| US-20070173482-A1 | Agents for preventing and treating disorders involving modulation of the RyR receptors | RYR1, RYR2, ATP2A1 | CYP3A4 1204/4885CYP2D6 576/4885SLC6A3 1098/4885 |
| US-10301299-B2 | Glycosidase inhibitors | GAA, BACE1, GBA3 | CYP3A4 1050/4885CYP2D6 438/4885SLC6A3 1218/4885 |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | KCNB2, KCNJ2, KCNJ5 | CYP3A4 72/4885CYP2D6 126/4885SLC6A3 160/4885 |
| US-20180093977-A1 | Glycosidase Inhibitors | GAA, BACE1, GBA3 | CYP3A4 1050/4885CYP2D6 438/4885SLC6A3 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.